Inclusion Criteria: Only participants who meet all the inclusion criteria will be
enrolled into the trial:

- Healthy infant aged 5-36 months at the time of first study vaccination

- Parent/guardian provides signed/thumb-printed informed consent

- Infant and parent/guardian resident in the study area villages and anticipated to be
available for vaccination and the duration of follow-up

Exclusion Criteria: The participant may not enter the trial if ANY of the following
apply:

- Clinically significant congenital abnormalities as judged by the PI or other
delegated individual.

- Clinically significant skin disorder (psoriasis, contact dermatitis etc.),
cardiovascular disease, respiratory disease, endocrine disorder, liver disease,
renal disease, gastrointestinal disease, neurological illness as judged by the PI or
other delegated individual.

- Weight-for-age Z score of less than -3 or other clinical signs of malnutrition.

- History of allergic reaction, significant IgE-mediated event, or anaphylaxis to
immunisation.

- History of allergic disease or reactions likely to be exacerbated by any component
of the vaccines.

- Sickle cell disease.

- Clinically significant laboratory abnormality at grade 2 or above as judged by the
PI or other delegated individual.

- Administration of immunoglobulins and/or any blood products within the three months
preceding the planned administration of the vaccine candidate.

- Receipt of any vaccine in the 14 days preceding enrolment, or planned receipt of any
other vaccine within 28 days following each study vaccination.

- History of vaccination with another malaria vaccine.

- Participation in another research study involving receipt of an investigational
product in the 30 days preceding enrolment, or planned use during the study period.

- Known maternal HIV infection (no testing will be done by the study team).

- Any confirmed or suspected immunosuppressive or immunodeficient state, including HIV
infection; asplenia; recurrent, severe infections and chronic (more than 14 days)
immunosuppressant medication within the past 6 months (for corticosteroids, this
will mean prednisone, or equivalent, ≥ 0.5 mg/kg/day; inhaled and topical steroids
are allowed).

- Any significant disease, disorder or situation which, in the opinion of the
Investigator, may either put the participants at risk because of participation in
the trial, or may influence the result of the trial, or the participant's ability to
participate in the trial.

The following adverse events associated with vaccine immunisation constitute absolute
contraindications to further administration of vaccine. If any of these events occur
during the study, the participant must be withdrawn and followed until resolution of the
event, as with any adverse event:

• Anaphylactic reaction following administration of vaccine.

The following adverse events constitute contraindications to administration of vaccine at
that point in time; if any one of these adverse events occurs at the time scheduled for
vaccination, the participant may be vaccinated at a later date, or withdrawn at the
discretion of the Investigator. The participant must be followed until resolution of the
event as with any adverse event:

- Acute disease at the time of vaccination (acute disease is defined as the presence
of a moderate or severe illness with or without fever or symptoms suggestive of
possible COVID-19 disease). All vaccines can be administered to persons with a minor
illness such as diarrhoea or mild upper respiratory infection without fever, i.e.
axillary temperature < 37.5°C.

- Temperature of >37.5°C (99.5°F) at the time of vaccination.